Phase Forward Teams with PharmaNet Development Group
November 04 2009 - 3:00AM
Business Wire
Phase Forward (NASDAQ: PFWD), a leading provider of data
management solutions for clinical trials and drug safety, today
announced a multi-year agreement with PharmaNet Development Group,
Inc., a global drug development services company, that enables
PharmaNet to offer Phase Forward’s InForm™ electronic data capture
(EDC) solution to PharmaNet customers worldwide. PharmaNet provides
a comprehensive range of services to the pharmaceutical,
biotechnology, generic drug and medical device industries that
includes clinical trial data management.
“We chose to team with Phase Forward on the basis of our
successful collaboration on behalf of several pharmaceutical
companies,” said Thomas Newman, M.D., President, PharmaNet Late
Stage Development. “That experience indicated the complementary
nature of Phase Forward’s established leadership in EDC technology
solutions and our expertise in providing clinical trial services to
a broad range of industries. We look forward to extending to other
customers the success our work together has already achieved.”
“Customers are turning to PharmaNet for its proven expertise in
providing the critical services infrastructure required to optimize
the clinical trial process,” said Steve Powell, senior vice
president, Phase Forward. “Our InForm EDC solution is a perfect
addition to PharmaNet’s expertise and we look forward to building
on and expanding our work together.”
About PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc., a global drug development
services company, provides a comprehensive range of services to the
pharmaceutical, biotechnology, generic drug and medical device
industries. The Company offers early and late stage consulting,
Phase I clinical studies and bioanalytical analyses, and Phase II,
III and IV clinical development programs. With approximately 2,300
employees and 40 facilities throughout the world, PharmaNet is a
recognized leader in outsourced clinical development. For more
information, please visit our website at www.pharmanet.com.
About Phase Forward
Phase Forward is a leading provider of integrated data
management solutions for clinical trials and drug safety. Phase
Forward’s products and services have been utilized in over 10,000
clinical trials involving more than 1,000,000 clinical trial study
participants at over 300 organizations and regulatory agencies
worldwide including: AstraZeneca, Boston Scientific, Dana-Farber
Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration,
GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono,
Novartis, Novo Nordisk, PAREXEL International, Procter &
Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and
Healthcare Products Regulatory Agency. Additional information about
Phase Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. This press release
contains express or implied forward-looking statements relating to,
among other things, the performance and features of Phase Forward’s
products and services, demand for Phase Forward’s products and
services, future business and operations plans of a Phase Forward
customer, and the ability of Phase Forward’s customers to realize
benefits from the use of Phase Forward’s products and services.
These statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are
beyond Phase Forward's control, which could cause actual results to
differ materially from those contemplated in these forward-looking
statements. In particular, the risks and uncertainties include,
among other things, the ability of Phase Forward’s customers to
realize benefits from the use of its products and services, the
possibility that customers’ needs or plans may change over time,
the possibility that the level of demand for Phase Forward’s
products and services may vary, regulatory changes and competition.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. Phase Forward undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or
circumstances or otherwise. For additional disclosure regarding
these and other risks faced by Phase Forward, see the disclosure
contained in Phase Forward's public filings with the Securities and
Exchange Commission including, without limitation, its most recent
Annual Report on Form 10-K.
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jul 2023 to Jul 2024